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BACKGROUND AND PURPOSE
The Kaposi sarcoma (KS)-associated herpesvirus GPCR (vGPCR) is a key molecule in the pathogenesis of KS, where it increases
NF-κB gene expression and activates the NF-κB pathway. We investigated whether the less calcemic vitamin D analogue TX
527 inhibited the proliferation of endothelial cells transformed by vGPCR by modulation of the NF-κB pathway.
EXPERIMENTAL APPROACH
Endothelial cells transformed by vGPCR (SVEC-vGPCR) were treated with TX 527. Proliferation was measured by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and cell cycle by
flow cytometry. mRNA and protein levels were measured by real-time quantitative reverse transcriptase-PCR (qRT-PCR) and
immunoblot analysis respectively.
KEY RESULTS
TX 527, similar to bortezomib (0.5 nM), a proteasome inhibitor that inhibits the activation of NF-κB, reduced proliferation
and induced G0/G1 cell cycle arrest in SVEC-vGPCR. TX 527 like 1α,25(OH)2D3, biological active form of vitamin D, decreased
the activity of NF-κB comparable with the effect of bortezomib. Time-response studies showed that TX 527 significantly
decreased NF-κB and increased IκBα mRNA and protein levels. The increase of IκBα was accompanied by a reduction in
p65/NF-κB translocation to the nucleus. These responses were abolished when vitamin D receptor (VDR) expression was
suppressed by stable transfection of shRNA against VDR. In parallel with NF-κB inhibition, there was a down-regulation of
inflammatory genes such as IL-6, CCL2/MCP and CCL20/MIP3α.
CONCLUSIONS AND IMPLICATIONS
These results suggest that the anti-proliferative effects of the vitamin D analogue TX 527 in SVEC-vGPCR occur by modulation
of the NF-κB pathway and are VDR dependent.
Abbreviations
CCL2/MCP, chemokine (C-C motif) ligand 2/monocyte chemotactic protein-1; CCL20/MIP3α, chemokine (C-C motif)
ligand 20/macrophage inflammatory protein-3; IL-8/CXCL8, interleukin 8; IκBα, nuclear factor of κ light polypeptide
gene enhancer in B-cells inhibitor, α; KS, Kaposi sarcoma; MEFs, mouse embryonic fibroblasts; MIP-1/CCL3,
macrophage inflammatory protein 1-α/chemokine (C-C motif) ligand 3; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; qRT-PCR, real-time quantitative reverse
transcriptase-PCR; RelA, factor de transcripción p65; RelB, v-rel reticuloendotheliosis viral oncogene homologue B;
SVEC-vGPCR, endothelial cells transformed by vGPCR; TX 527, [19-nor-14,20-bisepi-23-yne-1,25(OH)2D3]; VDR, vitamin
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Introduction
1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3, calcitriol], the
most biologically active form of vitamin D, maintains
calcium homeostasis through its actions in intestine, bone,
kidneys and the parathyroid glands (Feldman et al., 2007). In
addition to its classical effects, 1α,25(OH)2D3 exerts anti-
proliferative, pro-apoptotic and pro-differentiating actions
on various malignant cells and exhibits anti-inflammatory
effects through inhibition of pro-inflammatory cytokines and
NF-κB signalling (Krishnan and Feldman, 2011). Most of the
activity of 1α,25(OH)2D3 is mediated by the vitamin D recep-
tor (VDR), a member of the nuclear receptor superfamily
(Haussler et al., 1998). The VDR is present not only in cells
and tissues involved in calcium regulation but also in a wide
variety of other cells including neoplastic cells (Feldman
et al., 2007). In recent years, it has been recognized that
1α,25(OH)2D3 exerts anti-proliferative and pro-differentiating
effects in several malignant cells, and retards the develop-
ment and growth of tumours in animal models raising the
possibility of its use as an anticancer agent (Deeb et al., 2007;
Krishnan et al., 2010). However, because of its calcemic
effects, such as hypercalcemia, hypercalciuria and increased
bone resorption, the use of the hormone for therapeutic
purposes is limited (Eelen et al., 2007). The synthesis of ana-
logues with less calcemic activity tries to overcome this
problem (Verlinden et al., 2000; Bouillon et al., 2005; Eelen
et al., 2007). One of such analogues, TX 527 [19-nor-14,20-
bisepi-23-yne-1,25(OH)2D3] has been shown to possess mark-
edly diminished in vivo calcemic effects in combination with
enhanced anti-proliferative and pro-differentiating capacities
on normal and malignant cell types when compared with
1α,25(OH)2D3 (Van Etten et al., 2000; Verlinden et al., 2000).
In addition, TX 527 has enhanced immune regulatory capaci-
ties when compared with the parental compound (van Etten
et al., 2003; Baeke et al., 2011) which makes this analogue a
suitable candidate to treat hyper-proliferative and inflamma-
tory disorders.
Kaposi’s sarcoma (KS) is an angio-proliferative tumour
and is the most common cancer in HIV-infected untreated
individuals. KS-associated herpes virus (KSHV; also known as
human herpes virus 8) is the infectious cause of this neo-
plasm (Martin and Gutkind, 2009; Mesri et al., 2010). The
KS-associated herpes virus GPCR (KSHV-GPCR) is a key mol-
ecule in the pathogenesis of KS. Persistent expression and
activity of viral GPCR (vGPCR) is required for tumour main-
tenance (Montaner et al., 2006). Thus, vGPCR and its regu-
lated signalling pathways may represent suitable candidates
for KS treatment (Martin et al., 2008). vGPCR contributes to
KS development through its potent transforming and pro-
angiogenic functions. At the molecular level, the angiogenic
and paracrine transforming effect of vGPCR involves the acti-
vation of multiple MAPKs and small GTPases of the rho
family which activities converge in the nucleus to control
transcription factors such as hypoxia-inducible factor 1α and
AP-1 and promotes the expression of pro-inflammatory mol-
ecules, IL-6, IL-8/CXCL8 and MIP-1/CCL3 (Sodhi et al., 2000;
2001; Montaner et al., 2001; 2004; Martin et al., 2008). NF-κB
consists of a family of transcription factors including p65
(RelA), p105/p50, p100/p52, RelB and c-Rel. It has been deter-
mined that NF-κB gene expression is increased in KS and that
vGPCR potently activates the NF-κB pathway which is
required for direct induction of neoplasia by vGPCR, thus
being an important therapeutic target for the treatment of KS
(Martin et al., 2008; Martin and Gutkind, 2009; Gupta et al.,
2010). NF-κB regulates the transcription of a wide array of
genes involved in inflammation and also in growth regula-
tion, apoptosis, cancer invasion/metastasis, tumour promo-
tion and carcinogenesis (Aggarwal, 2004; Gupta et al., 2010).
We have previously demonstrated that 1α,25(OH)2D3 and
TX 527 have anti-proliferative effects on the growth of
endothelial cells transformed by the vGPCR in vitro and in
vivo by a mechanism that depends on VDR expression
(González Pardo et al., 2010). Furthermore, down-regulation
of the NF-κB pathway by 1α,25(OH)2D3 in vGPCR cells was
found to be part of the mechanism of inhibition (Gonzalez
Pardo et al., 2012). In this work, we investigated whether the
analogue TX 527 similar to 1α,25(OH)2D3 inhibits the NF-κB
pathway and controls the expression of inflammatory genes
and the proliferation of endothelial cells transformed by
KS-associated herpes virus GPCR in a VDR-dependent
manner.
Methods
Chemicals and reagents
The vitamin D analogue TX 527, originally synthesized by M.
Vandewalle and P. De Clercq (University of Ghent, Belgium),
was provided by Théramex (Monte Carlo, Monaco). Immo-
bilon P (PVDF) membranes and the antibiotic G418 were
supplied by Sigma-Aldrich (St. Louis, MO, USA). Puromycin
was provided by Invivogen (San Diego, CA, USA). The anti-
bodies used mouse monoclonal anti-VDR (Affinity Biorea-
gents, Golden, CO, USA), rabbit polyclonal anti-NF-κB
and mouse monoclonal IκBα (Cell Signalling Technology,
Danvers, MA, USA); anti-tubulin, anti-lamin B, anti-actin,
anti-rabbit, anti-mouse and anti-rat horseradish peroxidase–
conjugated secondary antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). PI/RNase staining buffer and CellQuest
Pro were obtained from BD Pharmigen (San Jose, CA, USA).
High pure RNA isolation kit was provided by Roche Applied
Science (Indianapolis, IN, USA). Superscript II reverse tran-
scriptase was acquired from Invitrogen (Gent, Belgium). PCR
primers and fluorogenic probes for mouse RelA (NF-κB),
IκBα and β-actin were purchased from Eurogentec (Seraing,
Belgium). MIP3-α, MCP primers were received from Dr. C.
Mathieu (Laboratory of Clinical and Experimental Endocri-
nology, KU Leuven, Leuven, Belgium). TX 527 was used at
10 nM because this concentration consistently shows anti-
proliferative effects (Verlinden et al., 2000; González Pardo
et al., 2010).
Cell lines and transfections
SV-40 immortalized murine endothelial cells stably express-
ing vGPCR full length (SVEC- vGPCR) were used. Stable over-
expression of vGPCR promotes tumour formation when
injected into immune-suppressed mice and induces angio-
genic lesions similar to those developed in KS (Montaner
et al., 2003; González Pardo et al., 2010). Transfected cells
were selected with 500 μg·mL−1 G418. Stable SVEC-vGPCR
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endothelial cells targeted with small hairpin RNA against
mouse VDR (vGPCR-shVDR) or control shRNA (vGPCR-
shctrl) were obtained by transduction of lentiviral particles
(González Pardo et al., 2010). The stable cell lines were
selected with 2 μg·mL−1 puromycin and the medium was
freshly changed every other day. VDR knock-down was moni-
tored by Western blot analysis.
Cell cycle analysis
Cell cycle distribution was analysed by flow cytometry. SVEC-
vGPCR cells were incubated with TX 527 (10 nM) or vehicle
(0.01% ethanol) and bortezomib (0.5 nM) alone or in com-
bination with the analogue for 24 h. Then they were trypsi-
nized, washed once with PBS, and fixed in 70% ethanol for at
least 1 h at −20°C. Fixed cells were washed two times with PBS
containing 0.05% Tween 20 and incubated with PI/RNase
staining buffer for 15 min at room temperature in the dark.
The stained cells were analysed in a FACS Calibur flow cytom-
eter (Becton Dickinson, Franklin Lakes, NJ, USA). The
program used for the acquisition and analysis of the samples
was the CellQuest Pro.
Proliferation assays
SVEC-vGPCR cells were seeded in 96-well plates at 2000
cells per well. After overnight growth, the cells were starved
for 24 h and then treated with TX 527 (10 nM) or vehicle
(0.01% ethanol) in the presence or absence of bortezomib
(0.5 nM) in triplicate in DMEM 2% FBS for 48 h. CellTiter
96® AQueous one solution cell proliferation assay containing
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) was used to
determine cell proliferation according to the manufacturer’s
instructions. Absorbance was measured at 490 nm.
NF-κB activity assay
The transcription factor kit for NF-κB p65 from Thermo Sci-
entific (Pierce Biotechnology, Rockford, IL, USA) was used to
measure the activity of NF-κB from nuclear extracts following
manufacturer’s protocol as previously reported (Gonzalez
Pardo et al., 2012). Chemiluminescence reaction was cap-
tured with a microplate reader Synergy HT Biotek (Biotek
Instruments Inc., Highland Park, VT, USA).
SDS-PAGE and Western blot analysis
Whole-cell lysates from cultures treated with TX 527 as indi-
cated for each experiment and their protein content deter-
mined by the Bradford procedure (Bradford, 1976) were
resolved by SDS-PAGE and transferred to PVDF membranes.
Western blot analyses were performed as reported before
(Gonzalez Pardo et al., 2006). Antibodies used include
monoclonal anti-VDR (1:1500), rabbit anti-NF-κB/p65
(1:2000), anti-IκBα (1:3000), anti-tubulin (1:1500), anti-actin
(1:10 000), anti-lamin B (1:1000) combined with anti-rabbit
(1:10 000), anti-mouse (1:5000), anti-rat (1:5000) or anti-goat
(1:20 000) horseradish peroxidase–conjugated secondary
antibodies.
Quantitative real-time PCR
Total RNA for real-time quantitative reverse transcriptase-PCR
(qRT-PCR) analysis was isolated using the high pure RNA
isolation kit (Roche). RNA (0.5–1 μg) was reverse transcribed
using the Superscript II reverse transcriptase and qRT-PCR
reactions were performed on the resulting cDNA (2 μL of
cDNA; dilution 1/10) in a 7500 RT-PCR system (Applied Bio-
systems, Carlsbad, CA, USA). Specific primers were used to
detect RelA/NF-κB, IκBα, VDR, IL-6, MCP, MIP3α levels and
β-actin to normalize gene expression (Gonzalez Pardo et al.,
2012). Sequences of forward/reverse primers and detection
probes for inflammatory genes (IL-6, MCP, MIP3α) were
designed by Dr. C. Mathieu (Laboratory of Clinical and
Experimental Endocrinology, KU Leuven, Leuven, Belgium).
Subcellular fractionation
SVEC-vGPCR stabling expressing shRNA against VDR
(vGPCR-shVDR) or control shRNA (vGPCR-shctrl) was cul-
tured in p100 dishes, treated with TX 527, and scrapped in
ice-cold TES buffer (50 mM Tris–HCl pH 7.4, 1 mM EDTA,
250 mM sucrose) containing 1 mM DTT and protease inhibi-
tors (0.5 mM PMSF, 20 μg·mL−1 aprotinin and 20 μg·mL−1
leupeptin). Homogenization was carried out as previously
reported to obtain nuclear and cytosol fraction (Gonzalez
Pardo et al., 2012). Anti-lamin B antibody was employed for
the immune detection of the nuclear protein marker lamin B
in the different fractions and tubulin as cytosolic marker.
Statistical analysis
Data are shown as means ± SD. Results were analysed by the
two-tailed t-test to evaluate differences between control
(vehicle) and treated conditions 1α,25(OH)2D3, TX 527 or
bortezomib. A P-value <0.01 (**) and <0.05 (*) was considered
highly statistically significant and statistically significant
respectively.
Results
Inhibition of proliferation and cell cycle arrest
by TX 527 is NF-κB dependent
To investigate whether the vitamin D analogue TX 527 exerts
its growth inhibitory effects through the regulation of NF-κB,
proliferation and cell cycle assays were carried out in SVEC-
vGPCR cells treated with TX 527 (10 nM) or vehicle (0.01%
ethanol) in the presence or absence of bortezomib (0.5 nM)
in DMEM with 2% FBS for 24–48 h. Bortezomib at low
nanomolar concentration is sufficient to inhibit the activa-
tion of NF-κB (Blackburn et al., 2010). Proliferation was
measured using the CellTiter 96 AQueous one solution cell
proliferation assay as described in Methods section. The
results shown in Figure 1A demonstrated that TX 527 signifi-
cantly decreased the proliferation of SVEC-vGPCR cells (16%
after 48 h of incubation). Bortezomib alone or in combina-
tion with TX 527 also significantly decreased (26%) the pro-
liferation of SVEC-vGPCR cells. To investigate the effect of TX
527 on the progression of the cell cycle, the percentages of
cells in the G0/G1, S and G2/M phases were determined by
flow cytometry analysis of propidium iodide stained cells. As
shown in Figure 1B, TX 527 increased the percentage of
SVEC-vGPCR cells in G0/G1 (from 53 to 61% at 24 h), which
was accompanied by a reduction in the percentage of cells in
the S phase (from 27 to 22%). When the cells were incubated
BJPTX 527 down-regulates the NF-κB pathway
British Journal of Pharmacology (2013) 169 1635–1645 1637
with the NF-κB inhibitor bortezomib, the response was
similar to TX 527 and the combination of both compounds
did not significantly enhance the inhibitory effect of the
analogue.
TX 527 similar to 1α,25(OH)2D3 inhibits
NF-κB activity in SVEC-vGPCR
The transcriptional activity of the active form of NF-κB p65
was assayed in nuclear extracts from SVEC-vGPCR. To that
end, SVEC-vGPCR cells were treated with 1α,25(OH)2D3 and
TX 527 (10 nM, 48 h) and bortezomib (0.5 nM) alone or in
combination with TX 527. TNF-α-activated HeLa cell nuclear
extracts were included in the assay as positive control. The
active transcription factor (from nuclear extracts) bound to
DNA consensus sequence or buffer alone (negative control)
was incubated with specific primary antibody (NF-κB p65)
followed by a secondary HRP-conjugated antibody, and
chemiluminescence was finally detected on a luminometer.
The results shown in Figure 2 demonstrated that TX 527
significantly decreased the transcriptional activity (65%) of
NF-κB being more effective than 1α,25(OH)2D3 (43%). Bort-
ezomib also decreased NF-κB transcriptional activity (68%)
and in combination with TX 527 (62%) did not significantly
enhance vitamin D analogue inhibitory effect.
TX 527 decreases NF-κB and increases IκBα
mRNA and protein levels
The classic form of NF-κB is the heterodimer p50/p65 that
contains the transcriptional activation domain and is seques-
tered in the cytoplasm as an inactive complex by the inhibi-
tory protein IκB (Hayden and Ghosh, 2004). To investigate
whether the reduced transcriptional activity of NF-κB could
be related to changes in the expression levels of p65 and its
inhibitory protein, SVEC-vGPCR cells were plated and incu-
bated with TX 527 (10 nM) or vehicle (0.01% ethanol) in the
presence of 2% FBS for 3–72 h. Total RNA was isolated and
reverse transcribed followed by qRT-PCR using specific
primers to detect NF-κB and IκBα mRNA levels and β-actin
mRNA to normalize gene expression. The results shown in
Figure 3A demonstrated that TX 527 significantly decreased
NF-κB mRNA levels (20%) and increased IκBα mRNA levels in
a time-dependent fashion (50–80%). In parallel experiments,
total proteins from whole-cell lysates were prepared and
subject to Western blot analysis with anti-NF-κB and IκBα
Figure 1
Inhibition of proliferation and cell cycle arrest is induced by TX 527 and bortezomib. SVEC-vGPCR cells were plated and incubated in serum-free
DMEM for 24 h. After overnight growth, cells were treated with 10 nM TX 527 or vehicle (ctrl), bortezomib (0.5 nM) or combination of both TX
527 and bortezomib in DMEM 2% BSA for 24–48 h. (A) Proliferation assay was carried out using MTS as described in Methods section. Absorbance
was measured at 490 nm. The data from three independent experiments are means ± SEM performed in triplicate. Significant differences between
control and treated conditions are indicated. *P < 0.05, **P < 0.01. (B) Cells were then stained with propidium iodide and the distribution of cells
in the different phases of the cell cycle was analysed by flow cytometry. The program CellQuest was used for acquisition and analysis of the FACS
scans (C). A representative cell cycle analysis and percentages of each phase are shown. Data represent means ± SD of three independent
experiments done in triplicate. Significant differences between cell cycle distribution of control and stimulated cells are indicated. *P < 0.05, **P
< 0.01. G0/G1= cells in G0/G1 cell cycle phases; S = cells in S cell cycle phase; G2/M = cells in G2/M cell cycle phases.
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antibodies. The results in Figure 3B showed that TX 527 mod-
erately reduced the protein levels of NF-κB and significantly
increased IκBα protein levels.
Decreased nuclear levels of NF-κB protein
induced by TX 527 are VDR dependent
To investigate if TX 527-dependent increase of IκBα could
retain p65/NF-κB in the cytosol, thus decreasing the activity
of NF-κB, the localization of NF-κB and IκBα was evaluated.
SVEC-vGPCR cells were cultured and treated with TX 527
(10 nM, 3–24 h) or vehicle (0.01% ethanol). The cells were
collected in TES buffer and subject to differential centrifuga-
tion to obtain enriched nuclear and cytosolic fractions, as
described in Methods section. Western blot analysis with
anti-NF-κB and IκBα antibodies was performed and lamin B
and tubulin were used to show loading controls of nuclear
and cytosolic fraction respectively. The results in Figure 4A
showed that NF-κB was present in the nucleus and upon
TX 527 exposure (3–24 h) its localization decreased in the
nucleus and increased in cytosol, whereas IκBα increases in
both compartments. To determine whether an increase in the
expression of the VDR was part of the mechanism of action,
stable SVEC-vGPCR endothelial cells targeted with small
hairpin RNA against mouse VDR (vGPCR-shVDR) or control
shRNA (vGPCR-shctrl) were cultured and treated with TX 527
(10 nM, 24 h) or vehicle (0.01% ethanol). The results shown
in Figure 4B demonstrated that TX 527 increased the amount
of VDR and induced its translocation to the nucleus. The
translocation of NF-κB was decreased in SVEC-vGPCR cells
when treated with TX 527, whereas NF-κB nuclear protein
levels were restored when the VDR was knocked down in
vGPCR-shVDR cells. The localization of IκBα protein was not
affected.
Dependence of VDR on NF-κB and IκBα
mRNA expression
To further investigate the participation of VDR on the mRNA
expression of NF-κB and its inhibitory protein IκBα, the stable
VDR knock-down cell line vGPCR-shVDR was used. To that
end, vGPCR-shctrl and vGPCR-shVDR cells were plated and
incubated with TX 527 (10 nM) or vehicle (0.01% ethanol)
in the presence of 2% FBS for 24 h. Total RNA was isolated
and reverse transcribed followed by qRT-PCR using specific
primers as described in Figure 3A. First, VDR expression was
evaluated to determine the VDR knock-down (Figure 5A). In
control cells (vGPCR-shctrl), VDR and IκBα mRNA signifi-
cantly increased whereas NF-κB decreased upon TX 527 treat-
ment. The induction of IκBα and inhibition of NF-κB
expression by TX 527 were blunted when VDR was knocked
down in vGPCR-shVDR cells (Figure 5A). To further investi-
gate whether the changes in mRNA levels were reflected in
changes in protein expression, Western blots from parallel
experiments were performed (Figure 5B). Cell lysates were
prepared and subject to immunoblot analysis with anti-VDR,
NF-κB and IκBα antibodies. The results in Figure 5B showed
that although the VDR induced by TX 527 was not com-
pletely blocked, reduced NF-κB and increased IκBα protein
levels were still observed. As bortezomib has shown to inhibit
NF-κB activity and did not enhance the effect of TX 527 when
they were incubated together, this raises the possibility that
both agents could act by the same mechanism. To evaluate
this possibility, SVEC-vGPCR cells were cultured and treated
with TX 527 (10 nM, 24 h) or vehicle (0.01% ethanol) in the
presence or absence of bortezomib (0.5 nM) in 2% FBS. As
shown in Figure 5C, bortezomib alone reduced NF-κB and
increased IκBα mRNA expression similarly to TX 527. No
additive effects were found when both bortezomib and TX
527 were added together.
Down-regulation of NF-κB by TX 527
controls inflammatory gene expression
Expression and secretion of pro-inflammatory mediators are
important for autocrine and paracrine neoplasia induced by
vGPCR in endothelial cells (Martin and Gutkind, 2009; Mesri
et al., 2010). We investigated whether TX 527 modulates
cytokine IL-6 and chemokines CCL2/MCP and CCL20/MIP3α
gene expression and whether the effects are VDR dependent.
To this end, vGPCR-shctrl and vGPCR-shVDR cells were
plated and incubated with TX 527 (10 nM) or vehicle (0.01%
ethanol) in the presence of 2% FBS for 24 h. RNA was isolated
and reverse transcribed followed by qRT-PCR using specific
primers as described in Methods section. As shown in
Figure 6A, TX 527 significantly decreased the expression of
IL-6 (60%, P < 0.01), MCP (57%, P < 0.01) and MIP3α (39%,
P < 0.01) in vGPCR endothelial cells (vGPCR-shctrl) com-
pared with vehicle-treated cells. When the VDR was knocked
down, the effect of TX 527 on the expression of IL-6 was
partially reversed (21%, P = 0.03) whereas MCP and MIP3α
gene expression was not statistically affected. To investigate
the involvement of NF-κB on the effects of TX 527, SVEC-
vGPCR cells incubated with NF-κB inhibitor bortezomib
(0.5 nM) alone or in combination with TX 527 (10 nM) were
cultured for 24 h (Figure 6B). Bortezomib by itself signifi-
cantly reduced the expression of IL-6 (33%, P < 0.01), MCP
Figure 2
TX 527, similar to 1α,25(OH)2D3, inhibits NF-κB activity in SVEC-
vGPCR. SVEC-vGPCR cells were treated with 10 nM 1α,25(OH)2D3
and TX 527 or vehicle (0.01% ethanol), bortezomib (0.5 nM), and
combination of both TX 527 and bortezomib in DMEM 2% BSA for
48 h. TNFα-activated HeLa cell nuclear extracts and buffer for anti-
bodies used alone were included in the assay as positive and negative
controls respectively. NF-κB activity was measured by chemilumines-
cence reaction captured with a microplate reader as described in
Methods section. The data from each experiment are means ± SD
performed in duplicate. Significant differences between control
(vehicle) and treated conditions are indicated. *P < 0.05, **P < 0.01.
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(24%, P < 0.01) and MIP3α (80%, P < 0.01) compared with
vehicle-treated cells but did not significantly potentiate the
reduction in the expression of IL-6 (17%, P = 0.22) and MCP
(10%, P = 0.56) when combined with TX 527; however,
down-regulation of MIP3α by TX 527 was greatly enhanced
by bortezomib (73%, P < 0.01).
Discussion and conclusions
1α,25(OH)2D3 and its synthetic analogues have anti-
proliferative effects in many types of cancer and also possess
potent immune modulatory activities; however, the molecu-
lar mechanism of 1α,25(OH)2D3-mediated inflammatory gene
alteration and its participation in tumour development is not
yet fully understood. In addition to its principal function in
physiological immune reactions, NF-κB plays a pivotal role in
the generation and maintenance of malignancies (Nishikori,
2005). The classic form of NF-κB is the p65/p50 heterodimer
that contains the transcriptional activation domain and is
sequestered in the cytoplasm as an inactive complex by IκBα
(Baldwin, 1996). Acute stimuli such as TNF-α, LPS or phorbol
myristate acetate lead to the activation of IκB kinases which
in turn phosphorylate Ser32 and Ser36 within the N-terminal
response domain of IκB (Karin and Ben-Neriah, 2000). Phos-
phorylated IκB undergoes ubiquitination-dependent prote-
olysis and the release of IκB unmasks the nuclear localization
signal and results in the translocation of NF-κB to the
nucleus, followed by the activation of specific target genes
(Karin and Ben-Neriah, 2000). It has been described that IκB
proteins play an important role in the termination of NF-κB
activation. Newly synthesized IκBα enters the nucleus and
Figure 3
TX 527 decreases NF-κB and increases IκBα mRNA and protein levels. SVEC-vGPCR cells were cultured and treated with 10 nM TX 527 or vehicle
for 3–72 h as described in Methods section. (A) Total RNA was extracted and reverse transcribed (0.5–1 μg). At each of these time points, gene
expression of RelA (p65/NF-κB) IκBα and β-actin was assessed by qRT-PCR analysis. Data are expressed as a ratio between TX 527 versus
vehicle-treated samples normalized to β-actin RNA levels. The statistical significance of the data was evaluated using Student’s t-test. **P < 0.01,
*P < 0.05. (B) Cell lysates were prepared and subject to Western blot analysis with anti-NF-κB, IκBα and actin antibodies. The bands were
quantified by densitometry and the ratio between NF-κB, IκBα versus total protein (actin) from control and treated conditions was analysed
statistically by Student’s t-test. **P < 0.01, *P < 0.05. A representative immunoblot of three independent experiments is shown.
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binds NF-κB, thereby enhancing its dissociation from the
DNA (the affinity of NF-κB to IκB appears to be higher than its
affinity to κB sites on DNA) and causing its re-exportation to
the cytoplasm by means of a nuclear export sequence present
on IκBα. (Arenzana-Seisdedos et al., 1997). In this work, we
have demonstrated that the NF-κB pathway is regulated by
vitamin D analogue TX 527 at various levels. Moreover, data
show that TX 527 through reduction of NF-κB activity inhib-
its the proliferation of SVEC-vGPCR cells through the induc-
tion of cell cycle arrest (Figures 1 and 2). Reduced NF-κB
transcriptional activity was also observed in response to
1α,25(OH)2D3 in VDR-positive MCF-7 breast cancer cells (Tse
et al., 2010) and our previous work in KS cellular model
(Gonzalez Pardo et al., 2012). Moreover, NF-κB and IκBα
mRNA and protein levels (Figure 3) were also modulated by
the analogue similar to 1α,25(OH)2D3 (Tse et al., 2010). Of
interest, in connection to the mode of action of TX 527, it
has been reported that 20-hydroxy-vitamin D3, a product
Figure 4
Decreased levels of NF-κB protein induced by TX 527 are VDR dependent. Stable SVEC-vGPCR cells were cultured and treated with TX 527
(10 nM, 3–24 h) or vehicle (0.01% ethanol). Cells were collected in TES buffer and subject to differential centrifugation to obtain enriched nuclear
(N) and cytosolic fractions (C) as described in Methods section. (A) Western blot analyses with anti-NF-κB and IκBα antibodies were performed
and lamin B and tubulin were used to show loading controls of nuclear and cytosolic fraction respectively. (B) SVEC-vGPCR cells targeted with small
hairpin RNA against mouse VDR (vGPCR-shVDR) or control shRNA (vGPCR-shctrl) were treated with TX 527 (10 nM, 24 h) or vehicle (0.01%
ethanol), enriched nuclear and cytosolic fractions were obtained as in (A) and Western blots were also performed with VDR antibody.
Representative Western blots and its quantification by Image J (bar graphs) shown are representative of three independent experiments. The
statistical significance of the data was evaluated using Student’s t–test. *P < 0.05.
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of vitamin D3 hydroxylation by P450scc, decreases NF-κB
activity by increasing IκBα levels in human keratinocytes
(Janjetovic et al., 2009). In our research, TX 527 decreases
nuclear translocation of NF-κB by a mechanism that depends
on VDR expression (Figure 4). Supporting our data, TX 527
has been found to reduce nuclear translocation of NF-κB
in peripheral blood mononuclear cells from patients with
Chron’s disease compared with healthy subjects treated with
TX 527 possibly through a decrease in TNF-α production (Stio
et al., 2007). Furthermore, in keratinocytes lacking VDR,
20-hydroxy-vitamin D3 did not affect IkBα mRNA levels,
which indicates that VDR is required for its action on NF-κB
activity (Janjetovic et al., 2009). More recently, it has
been suggested that 1α,25(OH)2D3 suppressed inflammation
(induced by expression of plasminogen activator inhibitor-1)
by blocking NF-κB activity and its nuclear translocation
through the induction of IκBα in mouse embryonic fibro-
blasts (MEFs) (Chen et al., 2011). In addition, the Vitamin D
analogue paricalcitol has been shown to inhibit renal inflam-
mation by promoting VDR-mediated sequestration of NF-κB
and inhibiting the ability of p65 to trans-activate gene tran-
scription (Tan et al., 2008). In preliminary observations, we
found that phosphorylated IκBα was present in vehicle-
treated vGPCR cells, and after TX 527 stimulation total IκBα
increased and the ratio p-IκBα/total IκBα decreased and thus
NF-κB activation. A possible explanation is that p-IκBα under-
goes proteosomal degradation and the bulk of IκBα increases
rapidly rather than its phosphorylation. Nevertheless, further
experiments are needed to confirm this hypothesis. We have
also demonstrated that TX 527 induced a VDR-dependent
up-regulation of inhibitory protein IκBα (Figure 5A). Our
results are consistent with a study that shows a marked
decrease of basal levels of IκBα in VDR-deficient MEFs com-
pared with VDR-positive MEFs (Sun et al., 2006). A previous
study showed that IκBα may be a direct target gene of acti-
vated VDR because a DR3-type vitamin D-responsive element
was found in IκBα (NFκB1a) gene promoter (Wang et al.,
2005). On the contrary, other reports showed that nuclear
hormone receptors, such as PPAR (Delerive et al., 2002) and
GR (Deroo and Archer, 2001), may induce IκBα transcription
Figure 5
Dependence of VDR on NF-κB and IκBα mRNA expression modulated by TX 527. Stable SVEC-vGPCR cells targeted with small hairpin RNA against
mouse VDR (vGPCR-shVDR) or control shRNA (vGPCR-shctrl) were cultured and treated with TX 527 (10 nM, 24 h) or vehicle (0.01% ethanol)
for 24 h (A and B) or in the presence/absence of bortezomib (0.5 nM) (C). (A and C) Total RNA was extracted and reverse transcribed (0.5–1 μg).
Gene expression of RelA (NF-κB), IκBα and VDR was assessed by qRT-PCR analysis, normalized to β-actin RNA levels. The statistical significance
of the data was evaluated using Student’s t-test. **P < 0.01, *P < 0.05. The data shown are representative of three independent experiments done
in triplicate. (C) In parallel, total cell lysates were prepared and subject to Western blot analysis with anti-NF-κB, -IκBα and -tubulin antibodies.
Representative immunoblots from three independent experiments are shown.
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by a DNA-binding-independent manner. The expression of
pro-inflammatory mediators is important for autocrine and
paracrine neoplasia induced by vGPCR in endothelial cells
(Martin and Gutkind, 2009), suggesting that inhibition of
pro-inflammatory mediators could be important as therapeu-
tic strategy. We demonstrated that TX 527 reduced cytokine
IL-6 and chemokines CCL2/MCP and CCL20/MIP3α gene
expression by a mechanism that did not require direct par-
ticipation of the VDR but involves the inhibition of activated
NF-κB in SVEC-vGPCR cells (Figure 6). Several studies have
reported that 1α,25(OH)2D3 and analogues exhibit anti-
inflammatory and immune modulatory effects in various cell
types (Yee et al., 2005; Equils et al., 2006; Suzuki et al., 2009;
Baeke et al., 2010). In our cell system, we observed that bort-
ezomib inhibits NF-κB activity and modulates inflammatory
gene expression and that its action did not enhance TX 527
effects (Figures 1, 2, 5B and 6), therefore suggesting that
both agents may act through the same mechanism. Taken
together, our findings strongly suggest that the vitamin D
analogue TX 527 regulates the NF-κB pathway and indicates
that TX 527 through reduction of NF-κB activity inhibited
the proliferation of SVEC-vGPCR cells inducing cell cycle
arrest. The analogue strongly increased IκBα mRNA and
protein levels, and decreased the nuclear translocation of
NF-κB by a mechanism that depends on VDR expression.
The inhibition of nuclear NF-κB activity is implicated in TX
527-reduced cytokine IL-6 and chemokines CCL2/MCP and
CCL20/MIP3α gene expression in SVEC-vGPCR cells.
In conclusion, vitamin D analogue TX 527 exerts anti-
proliferative and anti-inflammatory effects in KS (SVEC-
vGPCR) cells by down-regulation of the NF-κB pathway. Due
to its hypocalcemic activity, TX 527 may be a suitable candi-
date to treat hyper-proliferative and inflammatory disorders,
although it is necessary to test its potential therapeutic prop-
erties in animal models bearing vGPCR tumours.
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